Resistin has been associated with obesity and type 2 diabetes. The elevated serum resistin level in human diabetes is often associated with a pro-inflammatory milieu. In vitro data suggest that C-reactive protein (CRP) significantly increases resistin expression in cultured human PBMC, yet the relationship in vivo is largely unknown. The purpose of this study was to determine the concentrations of CRP and resistin in women with polycystic ovary syndrome (PCOS) and to clarify whether or not there are correlations between CRP and resistin levels that have not previously been studied in PCOS in the context of resistin. Serum resistin and hsCRP levels of forty-five women with PCOS were analyzed. Compared with the control group, women with PCOS had significantly higher serum concentrations of resistin (p=0.009). Women with PCOS had higher hsCRP levels compared with controls, but these differences were not statistically significant (p>0.05). There was no correlation between serum resistin and hsCRP levels (r=0.128, p=0.404). Our study suggests that resistin concentrations was not associated with hsCRP levels © Versita Warsaw and Springer-Verlag Berlin Heidelberg.
Introduction
Polycystic ovary syndrome (PCOS) is the most common endocrine disease in women of reproductive age, with the incidence reported to be about 4-6% in this age group The prevalence of PCOS in the general population ranges from 3% to 12.4%.
PCOS is associated with anovulatory infertility, menstrual disturbances, hyperandrogenemia and clinical features of hyperandrogenism such as hirsutism and acne. During the last decade, research has revealed an association with hyperinsulinemia, insulin resistance and the metabolic syndrome, which could possibly result in increased morbidity due to type 2 diabetes mellitus (DM) and cardiovascular disease (CVD) [1] [2] [3] [4] [5] .
Resistin is a novel adipocyte-secreted hormone that belongs to the family of cystein-rich resistin-like molecules [6] . In mouse models, it was first described as a link between obesity and insulin resistance/diabetes [7] . However, in humans, the biological role and clinical significance of resistin is poorly understood. Previous data showed that in humans resistin is predominantly expressed in monocytes, macrophages, spleen and bone marrow-derived cells and also at very low levels in adipose cells [8] [9] [10] [11] . Pro-inflammatory cytokines and endotoxins could strongly increase resistin expression in human peripheral bood monocytes (PBMC) [11] [12] [13] [14] . Furthermore, recombinant human resistin was shown to upregulate proinflammatory cytokines and adhesion molecule expression, suggesting that resistin may play an important role in the host response to acute inflammation by a nuclear factor kappa B-dependent pathway [12, 13] . 90High-sensitivity C-reactive protein (hsCRP) is an acute phase reactant hepatically synthesized in response to IL-6 and TNF-alpha [15] . C-reactive protein (CRP), a marker of systemic inflammation, is associated with increased risk of cardiovascular disease [16] . CRP levels are <1.0 mg/dl in 98% of healthy persons. Even when relatively elevated within this 'normal' range, CRP has been shown to be predictive of a first cardiovascular event in previously healthy women [17] .
CRP significantly increases resistin expression in cultured human PBMC. Our aim in the present study was to assess the concentration of CRP and resistin in women with PCOS and to clarify whether or not there are correlations between CRP and resistin levels that have not previously been studied in PCOS in the context of resistin.
Material and Methods
We evaluated a group of 45 females with PCOS. The diagnosis of PCOS was made according to the Rotterdam criteria based on the presence of two of the three following critera: oligo-and/or anovulation, clinical and/or biochemical signs of hyperandrogenism and polycystic ovaries at ultrasound (US) [18] . Exclusion criteria included pregnancy, hypothyroidism, hyperthyroidism, hyperprolactinemia, Cushing's syndrome, congenital adrenal hyperplasia, androgen-secreting tumors, hypertension, current or previous (within the last 6 months) use of drugs that would affect the androgen level, as well as cigarette smoking, or use of anti-inflammatory drugs or other hormonal drugs during the last month. It also excluded women with current infections, asthma, collagenosis, neoplastic, autoimmune, cerebrovascular, metabolic or cardiovascular disorders .
Twenty non hirsute, regular cycling women, age and body mass index (BMI)-matched to the patients were enrolled as controls. The healthy state of the women in the control group was determined by medical history, physical examination, complete blood chemistry and US. Exclusion criteria for healthy controls were PCO at US and/or clinical or biochemical hyperandrogenism. Each women was examined to evaluate hirsutism according to the Ferriman-Gallwey score. Body mass index (BMI) was computed as weight divided by square of height (kg/m 2 ). Hormonal assay and US were performed during the early follicular phase, between the 3rd and 5th days of the patients' mentsrual cycle, if they were regularly cycling or at least 8 weeks after their last menstrual period if they were oligomenorrheic. The blood samples were taken in the fasting state between 08:00 and 09:00 hours. Plasma was removed and stored at -80 0 C until it was analyzed. The following biochemical markers in serum were measured: high sensitive CRP by the immunoturbidimetric method, using an Olympus 2700 automatic analyzer (Mishiama, Japan); testosterone and dehydroepiandrosterone sulfate (SDHEA) by radioimmunoassay (RIA), using a Gamma counter C-12 (DPC, LA, USA); and insulin by the Kemilüminesans İmmunometrik assay (IRMA), using an Immulite 2000 (LA, USA).
Resistin was measured using an enzyme-linked immunoassay (ELISA) kit (Cat. No.: RD191016100, BioVendor Laboratory Medicine, Czech Republic) with a low limit of sensitivity of 0.1 ng/ml and intra-and interassay CV of <3.4 and <6.9% respectively. The plasma sample was diluted 3-fold with ELISA buffer prior to assay.
Statistics
The Kolmogorov-Smirnov test was applied to both groups to test the normal distribution for each variable. Since none of the variables showed a normal distribution, all results are expressed with the median and range. Differences between the PCOS and control groups were 
Results
The study population included 45 women with PCOS and 20 healthy controls. Descriptive characteristics of the two groups are given in Table 1 . There was no significant difference in age and BMI. Compared with the control group, women with PCOS had significantly higher serum concentrations of DHEAS, free testesterone and resistin ( Figure 1 ) (p=0.03, p=0.000, p=0.009 respectively). The FG score was significantly higher in women with PCOS (p=0.000). Women with PCOS had higher hsCRP ( Figure 2 ) and insulin levels compared with controls, but these differences were not statistically significant.
Pearson correlation was calculated in order to define parameters associated with plasma levels of resistin and CRP. There was no correlation between resistin and hsCRP levels (r=0.128, p=0.404). Also, there was no correlation of BMI with hsCRP and resistin levels, while serum resistin levels were correlated with insulin levels (r=0.349, p=0.02). Linear regression model was calculated to further investigate whether or not hsCRP levels are predictors of resistin concentrations. Resistin concentrations were not associated with hsCRP levels (p>0.05), while insulin concentrations were associated with resistin levels (p=0.02) (Figure 3 ).
Discussion
Although it has been established that resistin is almost exclusively produced in adipose tissue [19, 20] , recent data showed that in humans, resistin is predominantly expressed in monocytes, macrophages, spleen and bone marrow-derived cells and also at very low levels in adipose cells [8] [9] [10] [11] . In our study, serum resistin levels were significantly higher in women with PCOS compared with BMI-matched healthy women. We did not find any correlation between resistin concentration in the serum and BMI. However, in other studies, serum resistin levels were significantly higher in women with PCOS and BMI>25 kg/m 2 compared with women with normal BMI, with or without PCOS [21] . Our present results demonstrate that women with PCOS have hyperresistinaemia and this finding is completely independent of the degree of obesity. Our findings apparently support the notion that resistin is predominantly produced in monocytes, macrophages, spleen and bone marrow-derived cells and also at very low levels in adipose cells [8] [9] [10] [11] . Evidence of chronic inflammation in PCOS was showed by the presence of several elevated markers such as CRP levels [22, 23] . The increased hsCRP levels in women with PCOS are in line with those in most reported data. However, contradictory data also have been reported [24, 25] . In our study, women with PCOS had higher hsCRP levels compared with controls, but this difference was not statistically significant.
Previous data showed that CRP could induce the expression of resistin in cultured human monocytes in a dose-and time-dependent manner. Also, it has been indicated that stimulation of macrophages in vitro with proinflammatory cytokines leads to a marked increase in resistin production [12, 25] . It was demonstrated that endotoxemia caused a dramatic increase in resistin [14] .
Thus, in humans, resistin appears to be induced during the inflammatory response. Therefore, we investigated whether or not serum resistin concentrations were associated with hsCRP in women with PCOS, but we did not find any correlation between resistin concentration and hsCRP in the serum.
In this study, women with PCOS had higher values of insulin than those of the control group, but this difference was not statistically significant. However, bivariate correlation analysis showed that resistin levels correlate positively with fasting insulin concentrations. Therefore, linear regression analysis was performed to assess independent relationships. It was found that resistin levels correlate with fasting insulin levels independent of BMI. Independent of BMI, the presence of increased insulin can be expected in women with PCOS because of increased resistin in the present study.
The modest hyperandrogenism charecteristic of PCOS has been proposed to be associated with insulin resistance [27] . However, androgen administration to healthy women does not produce insulin resistance of the same magnitude as that seen in PCOS [28] . In our study, we found that free testosterone levels do not correlate with any parameter. This observation is consistent with previous data demonstrating a lack of association between free testosterone and insulin and resistin levels in women with PCOS [29] .
In conclusion, we have shown that serum resistin levels were significantly higher in women with PCOS compared with BMI-matched healthy women. Also, women with PCOS had higher hsCRP levels compared with controls, but this difference was not statistically significant. We did not find any correlation between resistin concentration in the serum and hsCRP. Resistin levels were correlated positively with fasting insulin concentrations. The main factor predicting insulin levels in PCOS was resistin.
